DPYD polymorphisms and fluoropyrimidines: A UK clinical registry
Research type
Research Database
IRAS ID
316540
Contact name
Paul Ross
Contact email
Research summary
DPYD registry
REC name
London - Stanmore Research Ethics Committee
REC reference
22/LO/0696
Date of REC Opinion
6 Dec 2022
REC opinion
Further Information Favourable Opinion
Data collection arrangements
Data from all patients receiving fluoropyrimidines chemotherapy for all cancers at the hospital will be included in the database. This dataset will include patient demographics, the dates of major interventions or treatments, complications of treatments received for cancer and long term outcomes such as survival and recurrence of cancer. Data collected will be updated and checked for accuracy. Only anonymised data from all sites will be entered onto the REDCap platform. All results or publications resulting from this dataset will be anonymised.
Research programme
The results from research using the registry will be used to inform treatment decisions and care for patients receiving fluoropyrimidine chemotherapy with a DPYD mutation. Findings will inform patients of realistic intervention risks based on real world data in the registry. The results will also aim to predict outcomes based on specific prognostic signs.
Research database title
DPYD registry
Establishment organisation
Guy's and St Thomas' NHS Foundation Trust
Establishment organisation address
Guy's Hospital
16th Floor, Tower Wing
SE1 9RT